Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Aims To Synchronize With Global Drug Approvals By 2025

Executive Summary

China’s new Five-Year Plan for drug quality aims to address hurdles in clinical study ethics committee review while leaving out other restrictions including genetic material export and substandard clinical sites.

You may also be interested in...



China Clarifies Some Genetic Material Rules But More Regulatory Steps Urged

China provides some long-awaited clarifications regarding the review and approval of international multi-center clinical trials but some groups are still calling for further steps.

China Proposes Rolling Submissions For Innovative New Drugs

A revised regulatory approach in China will include rolling data submissions among new incentives for the development of innovative new drugs in a bid to further accelerate the approval of such products.

China Biotech Podcast: Shanghai Policy, US Draft Biosecure Bill, MNCs' China Strategy

Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel